Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

GTx's (GTXI) Enobosarm Positive In Phase II Study; Shares Up

By Zacks Investment ResearchStock MarketsJun 12, 2017 10:14PM ET
www.investing.com/analysis/gtx's-(gtxi)-enobosarm-positive-in-phase-ii-study;-shares-up-200194912
GTx's (GTXI) Enobosarm Positive In Phase II Study; Shares Up
By Zacks Investment Research   |  Jun 12, 2017 10:14PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

GTx, Inc.’s (NASDAQ:GTXI) shares have climbed almost 99% after the company announced positive preliminary data from a phase II study, evaluating the lead pipeline candidate enobosarm 3 mg (GTx-024) for treating postmenopausal women with stress urinary incontinence (SUI). Additional data will be presented later in 2017.

Shares of GTx have outperformed the Zacks classified Medical-Biomed/Genetics industry so far this year. The stock has gained 16.5% compared with the broader industry’s increase of 2.2%.



The proof-of-concept phase II study was initiated in the first quarter of 2016. In this study, enobosarm is administered to post-menopausal women who have showed SUI symptoms for more than six months.

The study revealed that women treated with enobosarm lead to a significant reduction in incontinence episodes per day with decrease in mean stress leaks by over 80% from baseline across 12 weeks. Adverse events reported in the study are minimal.

Notably, enobosarm has already been evaluated in 24 completed or ongoing clinical trials enrolling over 1,700 subjects, of which approximately 1,200 subjects were treated with enobosarm at doses, ranging from 0.1 mg to 100 mg.

Investors are reminded that presently the company is conducting another phase II study, evaluating enobosarm in patients whose advanced breast cancer is both estrogen receptor (ER) positive and androgen receptor (AR) positive.

Top-line data from the trial is expected in the third quarter of 2017. Additionally, enobosarm is also studied in another phase II study for treatment of patients with advanced AR triple-negative breast cancer (TNBC).

Per company’s press release, SUI affects up to 50% of adult women in the U.S. SUI is the most common type of urinary problem suffered by women. Hence, approval of the candidate as a drug would provide the company with access to a huge population base of patients suffering from the disease in the U.S.

Key Picks

Some favorably placed stocks in healthcare sector include VIVUS, Inc. (NASDAQ:VVUS) , Bayer (DE:BAYGN) AG (OTC:BAYRY) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) . While VIVUS and Bayer sports a Zacks Rank #1 (Strong Buy), Regeneron carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

VIVUS’s loss per share estimates narrowed from 50 cents to 39 cents for 2017 in last 60 days. The company posted positive earnings surprises in all four trailing quarters with an average beat of 233.69%.

Bayer’s earnings per share estimates increased from $8.75 to $8.89 for 2017 and from $9.41 to $9.57 for 2018, over last 30 days. The company posted positive earnings surprises in three of four trailing quarters with average beat of 10.25%.

Regeneron’s earnings per share estimates increased from $10.16 to $10.52 for 2017 and from $10.90 to $12.10, over last 60 days. The company posted positive earnings surprises in two of four trailing quarters with average beat of 0.45%.

Zacks' 2017 IPO Watch List

Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.

One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>



Bayer AG (BAYRY): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

VIVUS, Inc. (VVUS): Free Stock Analysis Report

Original post

Zacks Investment Research
GTx's (GTXI) Enobosarm Positive In Phase II Study; Shares Up
 

Related Articles

GTx's (GTXI) Enobosarm Positive In Phase II Study; Shares Up

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email